Helius Med Technolog (HSDT) 1.9640 $HSDT U.S. Army and

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Helius Med Technolog (HSDT) 1.9640 $HSDT

U.S. Army and Helius Medical Technologies Execute Sole Source Contract for the PoNS(TM) Device Testing and Development
Business Wire - Tue Jul 07, 9:15AM CDT
Helius Medical Technologies, Inc. (CSE:HSM) (OTCQB:HSDT) ("Helius" or the "Company" announced that NeuroHabilitation Corporation ("NHC", a division of Helius, successfully executed a sole source cost sharing contract with the U.S. Army Medical Research and Materiel Command (USAMRMC). The contract will support Helius' registrational trial investigating the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS(TM)), a non-invasive brain stimulation device that is being developed for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury (mTBI).

Helius Medical Technologies Announces Closing of CAD $875,558 Non-Brokered Private Placement
TheNewswire.ca - Fri Jun 26, 5:30PM CDT
(via Thenewswire.ca)

Helius Medical Technologies Announces Clinical Device Readiness for PoNS(TM) 4.0
Business Wire - Thu Jun 25, 11:21AM CDT
Helius Medical Technologies, Inc. (CSE: HSM) (OTCQB: HSDT) ("Helius" is pleased to announce that it has successfully released the first clinical version of the Portable Neuromodulation Stimulator (PoNS(TM)) 4.0 device. The PoNS 4.0 device is manufactured by Ximedica LLC and will be used in Helius' registrational clinical trial, to investigate its safety and effectiveness for the treatment of balance disorder caused by traumatic brain injury.

Helius Medical Technologies Announces Clinical Device Readiness for PoNS (tm) 4.0
TheNewswire.ca - Thu Jun 25, 8:19AM CDT
(via Thenewswire.ca)

Helius Medical Technologies Amends and Re-files Historical Financial Statements and Material Change Report
ACCESSWIRE - Thu Jun 04, 7:12PM CDT
NEWTOWN, PA / ACCESSWIRE / June 4, 2015 / Helius Medical Technologies, Inc. (CSE: HSM) (OTCQB: HSDT) ("HMT", or the "Company" - As a result of a review by the British Columbia Securities Commission, we are issuing the following press release to clarify our disclosure.

Helius Medical Technologies Achieves Full Enrollment in Canadian MS Feasibility Study
Business Wire - Wed May 20, 9:15AM CDT
Helius Medical Technologies ("Helius", "HMT", or the "Company" announced that it has achieved full enrollment for its Multiple Sclerosis pilot clinical trial at the Montreal Neurological Institute. The trial, "Examining the efficacy of non-invasive neuromodulation in reducing symptoms of Multiple Sclerosis," launched in February 2015, is a 14-subject, blinded feasibility study investigating Helius' Portable Neuromodulation Stimulator (PoNS(TM)) and physiotherapy protocol on the rehabilitation of balance and gait symptoms in subjects with Multiple Sclerosis.

Helius Medical Technologies Announces Closing of Cad $2,208,110 Non-Brokered Private Placement
ACCESSWIRE - Thu Apr 30, 5:07PM CDT
NEWTOWN, PA / ACCESSWIRE / April 30, 2015 / Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ("Helius", or the "Company" is pleased to announce that it has closed a non-brokered private placement (the "Financing" raising gross proceeds of CAD $2,208,110 (approximately USD $1,825,937) by the issuance of 849,273 units (each a "Unit" at a price of CAD $2.60 per Unit (USD $2.15 per Unit). Each Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a "Warrant". Each whole Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of approximately CAD $3.62 per share (USD $3.00 per share) for a period of thirty-six (36) months from the closing date of the Financing.

Helius Medical Technologies Inventors' Granted US Patent No. 14/341,141
Business Wire - Tue Apr 14, 9:20AM CDT
Helius Medical Technologies, Inc. (CSE:HSM)(OTCQB:HSDT) ("Helius", or the "Company" announced today that the US Patent and Trademark Office (USPTO) issued a third patent related to its Portable Neuromodulation Stimulation (PoNS(TM)) device and the associated therapeutic modality. U.S. Patent No. 14/341,141 "Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function", issued on April 10, 2015, is directed to a non-invasive neuromodulation therapy that uses intraoral cutaneous stimulation in conjunction with cognitive exercise.

Helius Medical Technologies to Start Its Registrational Clinical Trial
Business Wire - Mon Apr 13, 12:04PM CDT
Helius Medical Technologies, Inc. (CSE:HSM) (OTCQB:HSDT) ("Helius" is pleased to announce that it recently met with the US Food and Drug Administration ("FDA" or the "Agency" as part of the Agency's pre-submission (pre-sub) process regarding Helius's protocol for its double-blind, randomized, sham-controlled study of the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS(TM)) 4.0 device for cranial nerve noninvasive neuromodulation (CN-NINM) training in subjects with a chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI).

Helius Medical Technologies Grants Stock Options
ACCESSWIRE - Mon Mar 16, 4:49PM CDT
NEWTOWN, PA / ACCESSWIRE / March 16, 2015 / Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ( "Helius" or "the Company", a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announces that it has granted incentive stock options, exercisable to purchase up to an aggregate of 100,000 shares of the Company, to a director of Helius.

Helius Medical Technologies Announces First Three Subjects Enrolled in Canadian Multiple Sclerosis Feasibility Study
Business Wire - Thu Feb 19, 9:15AM CST
Helius Medical Technologies ("Helius", or the "Company" announced the enrollment of the first three subjects in the Multiple Sclerosis ("MS" feasibility study at the Montreal Neurological Institute and Hospital and Concordia's PERFORM Center. The trial, "Examining the efficacy of Non-invasive Neuromodulation in reducing symptoms of Multiple Sclerosis", is a double-blind, sham-controlled study of the safety and efficacy of Helius' Portable Neuromodulation Stimulator (PoNS(TM)) device, an investigational medical device that is designed to induce neuromodulation by stimulating the cranial nerves found in the tongue. A total of 14 subjects will receive treatment with the non-invasive brain stimulation device and concomitant physiotherapy designed to improve both balance and gait. The primary endpoint, at 14-weeks, is improvement in gait as quantified by the Dynamic Gait Index (DGI), Sensory Organization Test (SOT) and Functional Magnetic Resonance imaging (fMRI). The study is expected to conclude this summer.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 156

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
RCA Mount Dora Widens Addiction Care Insurance Reach

Updated Category News Views 129

Insurance paperwork rarely looks heroic, yet it can decide whether treatment starts before a crisis gets worse. Recovery Centers of America at Mount Dora has added Aetna and Cigna/Evernorth to its in-network roster for every level of substance use disorder care, a practical move with real consequences for patients and families across Central Florida. Coverage matters most...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 156

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 199

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 111

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 11

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 171

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 85

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 41

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 277

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategic Changes Ahead for Southwest Airlines Amid Challenges

Updated Category News Views 299

Southwest Airlines Faces Important Decisions for Recovery Southwest Airlines (NYSE: LUV) is preparing for critical decisions that will significantly impact its workforce, as the airline launches a key strategy to regain profitability. This move comes as pressures from activist investor Elliott Investment Management increase, highlighting a crucial moment for the company....

Continue Reading
Tetragon Financial Group: Insights from the 2024 Annual Report

Updated Category News Views 209

Tetragon Financial Group Limited Releases 2024 Annual Report Tetragon Financial Group Limited has recently published its 2024 Annual Report, a document that offers valuable insights into the organization’s performance and future direction. Investors can look forward to a detailed overview of the company’s accomplishments and strategic initiatives outlined in this...

Continue Reading
Hollyland Launches Affordable Lyra 4K Webcam with Pro Features

Updated Category News Views 189

Introducing the Hollyland Lyra 4K UHD Webcam Hollyland has launched an exciting new product in the world of online communication—the Lyra 4K UHD Webcam. Set to redefine entry-level webcams, this innovative device offers professional audio-visual capabilities without breaking the bank. Perfect for anyone from content creators to educators and remote workers, the Lyra...

Continue Reading
PEAK® Enhances Lineup with Innovative Antifreeze Solutions

Updated Category News Views 224

PEAK® Expands Product Offerings with Innovative Antifreeze Options PEAK's recent product refresh provides consumers with enhanced choices for antifreeze and coolant applications tailored to their vehicle needs. The company continually strives to innovate and lead in the automotive fluids sector. New Additions to PEAK® Product Line Old World Industries has unveiled...

Continue Reading
Transforming Backyards with Synthetic Grass: A Modern Solution

Updated Category News Views 127

Introducing the Benefits of Synthetic Grass For homeowners, particularly in busy urban areas, achieving a beautiful lawn can often feel like an uphill battle. The constant need for watering, mowing, and maintenance for natural grass, especially when pets are involved, can be daunting. This is where synthetic grass emerges as a revolutionary alternative, providing a...

Continue Reading